Acknowledgements and Financial Support
Financial support for this project was provided by CHOP Frontiers
Program Immune Dysregulation Team (DTT, EB, HB), National Institute of
Allergy and Infectious Diseases (NIAID) (US): R01AI121250 (EMB),
R01AI103280 (AOJ), R01AI123433 (AOJ), R21AI144472 (AOJ), K08 AI136660
(LVV), and K08AI135091(SH), Agency for Healthcare Research and Quality
(AHRQ) 5K12HS026393 (KC), National Cancer Institute (NCI) (US):
R01CA193776 (DTT), X01HD100702-01(DTT), 5UG1CA233249) (DTT), and
R01A1123538 (DTT), NIH Training in Virology T32-AI-007324 (EMA),
Leukemia and Lymphoma Society (DTT), Cookies for Kids Cancer (DTT),
Alex’s Lemonade Stand Foundation for Childhood Cancer (DTT), Children’s
Oncology Group (DTT), Stand UP 2 Cancer (DTT), Team Connor (HB), and
Kate Amato Foundations (HB). Burroughs Wellcome Fund CAMS (SH) and PATH
(AOJ), Clinical Immunology Society (SH), and American Academy of
Allergy, Asthma, and Immunology (SH). Serological studies were supported
by institutional funds from the University of Pennsylvania. CD was
supported by the Institute for Translational Medicine and Therapeutics
of the Perelman School of Medicine at the University of Pennsylvania. We
gratefully acknowledge the gift of plasmids of the receptor binding
domain (RBD) of the SARS-CoV-2 spike (S) protein from Florian Krammer,
Mt. Sinai and the gift of the RBD-specific monoclonal antibody CR3022
from Ian Wilson, Scripps Research Institute. We gratefully acknowledge
the providers who cared for these patients, and the generosity of the
patients and their families.